HBV Is Not a Game: Or Is It? Optimizing Your Approach to HBV ManagementPremiere Date: Tuesday, June 12, 2018
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, June 12, 2019
Note: Credit Is No Longer Available
|Joseph Ahn, MD, MS, FAASLD, FACG, AGAF
Professor of Medicine
Section Chief, Division of Gastroenterology and Hepatology
Director of Clinical Hepatology
Oregon Health & Science University
|Amy Shen Tang, MD
Director of Immigrant Health
North East Medical Services
San Francisco, CA
Missed opportunities, new challenges, a growing threat. Compared to 2014, cases of acute HBV infection increased 20.7% in 2015, fueled by the opioid epidemic which accounted for 59.4% of cases. 1,000 babies are infected each year through mother to child transmission. Barriers to vaccination, screening, and treatment - from providers and patients - can be broken down by best practice strategies driven by data. Is HBV a game? No, but that doesn't mean learning best practices strategies can't be.
Join our expert faculty for this interactive CME Outfitters recorded symposium with its goal of improving confidence to make practice changes that will result in improved screening, evaluation, treatment, and monitoring of individuals infected with chronic HBV. Test your knowledge of HBV along the way and see how you answer compared to the live audience from this symposium.
At the end of this CE activity, participants should be able to:
- In at-risk populations, document that appropriate patients have been screened for HBV in alignment with the best practice advice of the new ACP clinical guidelines.
- Initiate antiviral therapy in patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
- Establish regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe ACP clinical guidelines for screening appropriate at-risk patient populations for HBV and how to properly document.
- Summarize antiviral therapy for patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
- Explain regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.10 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Ahn reports that he is an advisory board member of Gilead.
Dr. Tang has no disclosures to report.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained fro the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).